🔗 Share this article

As America proceeds with sweeping revisions to its immunization recommendations, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by questioning Covid shots throughout the global health crisis and has zeroed in on alleged deaths following Covid immunization in her short time at the FDA.

Proposed Shifts to Pediatric Immunization Schedule

Agency leaders had intended to unveil major revisions to the pediatric immunization program in December, bringing the US with the Danish vaccine program, it is understood – a major change that would put the US out of alignment with a large portion of the international standard with no evidence for public health gain. The announcement has been pushed back until the new year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to speak at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this year.

Consolidating Power at the Agency

This interim role could signify a tighter collaboration between the drug and biologics centers as Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a renewed priority upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing certain childhood immunization guidelines in the US to become more in line with Denmark, a society with comprehensive healthcare and a number of inhabitants roughly the size of Wisconsin’s.

To date comments, she has continued to focus on vaccination policy – usually the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Concerns Over Expertise

The appointee has little discernible track record in pharmaceutical research, approval processes or leadership, which has been standard for former leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“She appears not to have the necessary background” for running the pharmaceutical oversight division, said Jonathan Howard. “She has not conducted a clinical trial. She is not versed in running a major agency. She has no expertise in pharmaceutical oversight.”

Past commissioners of the center would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, noted Janet Woodcock. “Frankly, she doesn’t have the sort of resume that former directors who led the center have had.”

CDER has an enormous workload at the agency, the former commissioner pointed out.

“Many people just pays attention on the novel medication approvals, but the generic drug division authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and so forth, and every single one must be managed,” Dr. Woodcock said. “The thing you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a substantial management aspect to the job, which oversees in excess of 5,000 personnel. “It’s a huge leadership role, if you perform it correctly,” Woodcock added.

Official Statement and Contentious Policies

When asked about inquiries about Høeg’s qualifications and whether this selection indicates greater collaboration among FDA leaders on immunizations, a representative stated that the “concerns are based on incorrect premises”.

“This background matches the functions of her position,” the spokesperson said, pointing to the time Dr. Høeg spent advising the agency head on “drug safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg takes over the commissioner’s new fast-track approval initiative, a contentious one-day drug-approval program that reportedly concerned her predecessors. “How are these medications being chosen for this voucher program? Who makes the choices?” Dr. Howard questioned. “There is a lot of confidentiality going on at the agency right now.”

Broadly speaking, he remarked, “the Food and Drug Administration seems to be moving towards more relaxed rules of all drugs, with the exception of shots.”

Public Track Record on Immunizations

With immunizations, Høeg has a more established, if troubling, track record, some experts said. She published a study using non-validated crowd-sourced reports to estimate the rate of myocarditis following Covid vaccination. She consulted for the Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to indicate Covid vaccines are riskier than they are.

Included in her “desired changes” for the current government included altering rules for recently developed shots and ending “unnecessary” immunizations, she remarked post-election on a audio program. At the FDA, Høeg has according to sources suggested barring teenage boys from receiving COVID-19 vaccines.

“She is an thorough ideologue who commences with her conclusions and reverse-engineers to retrofit the evidence in a highly deceptive, fraudulent manner,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with fellow skeptics, {like|